Evidence map›Paper›PMID 42186472›Full record

ArticleYonago acta medica2026

Topiramate-Responsive Myoclonic Status Epilepticus in a Child with Progressive Myoclonus Epilepsy Due to Neuronal Ceroid Lipofuscinosis Type 8: A Case Report.

Hirokazu Tsuchie, Yukino Kawanami, Go Yoshino, Tohru Okanishi, Yoshihiro Maegaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Yonago acta medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hirokazu TsuchieDivision of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan.
Yukino KawanamiDivision of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan.
Go YoshinoDivision of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan.
Tohru OkanishiDivision of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan.
Yoshihiro MaegakiDivision of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive myoclonus epilepsy (PME) is a severe developmental and epileptic encephalopathy characterized by drug-resistant seizures and progressive neurological regression. In the late stage, patients often develop myoclonic status epilepticus (MSE), for which an optimal treatment has not been established. Neuronal ceroid lipofuscinosis type 8 (NCL8), caused by pathogenic variants in the

Indexed as

childneuronal ceroid lipofuscinosesprogressive myoclonus epilepsystatus epilepticustopiramate

Identifiers

PMID42186472
PMCPMC13198968

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.